Apimeds Pharmaceuticals US Inc. (APUS)

$0.00

$0 (0%)
Last update: 07:00 PM EST
Day's range
$1.29
Day's range
$1.32

Apimeds Pharmaceuticals US Inc. Major Shareholders & Ownership History

Major Shareholder Name Reporting Date Shares Held Market Value Change in Shares Ownership
HEMENWAY TRUST CO LLC 05/07/2026 274.00 K $490.30 K   0.00% 2.52%
05/15/2026 95.93 K $171.62 K   100.00% 0.88%
GEODE CAPITAL MANAGEMENT, LLC 05/15/2026 40.05 K $71.67 K   14.80% 0.37%
VANGUARD FIDUCIARY TRUST CO 05/08/2026 24.04 K $43.01 K   100.00% 0.22%
TWO SIGMA SECURITIES, LLC 05/15/2026 10.55 K $18.88 K   100.00% 0.10%
UBS GROUP AG 05/05/2026 4.19 K $7.49 K   619.42% 0.04%
BANK OF AMERICA CORP /DE/ 05/18/2026 0 $0   -100.00% 0.00%
TOWER RESEARCH CAPITAL LLC (TRC) 05/15/2026 0 $0   -100.00% 0.00%
JANE STREET GROUP, LLC 05/12/2026 0 $0   -100.00% 0.00%

Apimeds Pharmaceuticals US Inc. institutional Ownership - FAQ's

During the previous two years, 9 institutional investors and hedge funds held shares of Apimeds Pharmaceuticals US Inc.. The most heavily invested institutionals were:

Hemenway Trust Co LLC: 274,000

GEODE CAPITAL MANAGEMENT, LLC: 40,051

VANGUARD FIDUCIARY TRUST CO: 24,039

TWO SIGMA SECURITIES, LLC: 10,550

UBS Group AG: 4,187

JANE STREET GROUP, LLC: 0

4.12% of Apimeds Pharmaceuticals US Inc. stock is owned by institutional investors.

Institutional investors have bought a total of 411.82 K shares in the last 24 months. This purchase volume represents approximately $539.48 K in transactions.